Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #182921 on Biotech Values
IanFromSI
10/18/14 6:42 PM
#182924 RE: genisi #182921
Well, they could at least go for mild to moderate, not the moderate to sever AD patients, as the latter are too far progressed to gain from any treatment.